Keith D. Ignotz
Directeur Général chez OcuMedic, Inc.
Profil
Keith D.
Ignotz was the founder of Guided Therapeutics, Inc. (founded in 1993) and Freedom Meditech, Inc. (founded in 2006), where he held the titles of President, Chief Operating Officer & Director and President & Director, respectively.
Currently, he is the President & Chief Executive Officer of OcuMedic, Inc. and a Trustee at Pennsylvania College of Optometry since 1990.
His former positions include President & Chief Executive Officer at DiaKine Therapeutics, Inc. (2009-2010), Director at Paradigm Medical Industries, Inc., Senior Vice President at Allergan Humphrey (1986-1992), and President at Humphrey Instruments, Inc. (1985-1986).
Mr. Ignotz holds an MBA from Pepperdine University and an undergraduate degree from San Jose State University.
Postes actifs de Keith D. Ignotz
| Sociétés | Poste | Début |
|---|---|---|
| Pennsylvania College of Optometry | Directeur/Membre du Conseil | 01/01/1990 |
OcuMedic, Inc.
 OcuMedic, Inc. Medical SpecialtiesHealth Technology OcuMedic, Inc. manufactures lens equipment. The company was founded by Mark Byrne and Paul Byrne and is headquartered in Mullica Hill, NJ. | Directeur Général | - |
Anciens postes connus de Keith D. Ignotz
| Sociétés | Poste | Fin |
|---|---|---|
DiaKine Therapeutics, Inc.
 DiaKine Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology DiaKine Therapeutics, Inc. is a start-up biopharmaceutical company developing new, proprietary drugs for unmet medical needs in diabetes and complications related to diabetes. These drugs have the potential to restate the diabetes market by stopping the progression of diabetes and reversing damage already caused by the disease. Because of their unique immune modulating and anti-inflammatory properties, these therapies may potentially benefit people with type 1 and type 2 diabetes and represent a total available market opportunity of approximately $13 billion. The Company's lead compound, Lisofylline (LSF), has had an excellent safety profile in clinical trials to date. LSF works at the cellular level by improving the function of insulin producing islet cells and protecting them from damage and premature death caused when the body's immune system turns on itself. This autoimmune action is the cause of type 1 diabetes and Latent Autoimmune Diabetes in Adults (LADA), which combined affect approximately three million people in the U.S. About three million people with type 2 diabetes use insulin due to diminished insulin production and an increasing resistance to insulin. A primary focus of DiaKine's research and development is on its next generation of orally bioavailable immune modulators which have an improved spectrum of action to LSF. Two such compounds, DT22669 and DT23552, have been identified for further development and are examples of the extensive library of analogs and new structures in its patent portfolio that await discovery for future indications. | Directeur Général | 01/01/2010 |
Allergan Humphrey
 Allergan Humphrey Financial ConglomeratesFinance Allergan Humphrey was engaged in making microprocessor based ophthalmic diagnostic equipment. The company was headquartered in San Leandro, CA. | Corporate Officer/Principal | - |
| Humphrey Instruments, Inc. | President | - |
Freedom Meditech, Inc.
 Freedom Meditech, Inc. Medical SpecialtiesHealth Technology Freedom Meditech, Inc. operates as a medical device company which focuses on the development and commercialization of ophthalmic medical devices. It specializes in devices for the detection, monitoring, and management of chronic diseases, such as diabetes. The company was founded by Craig H. Misrach and Keith D. Ignotz in December 2006 and is headquartered in San Diego, CA. | Fondateur | - |
| GUIDED THERAPEUTICS, INC. | Fondateur | - |
Formation de Keith D. Ignotz
| San Jose State University | Undergraduate Degree |
| Pepperdine University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| PARADIGM MEDICAL INDUSTRIES, INC. | Health Technology |
| GUIDED THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
DiaKine Therapeutics, Inc.
DiaKine Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology DiaKine Therapeutics, Inc. is a start-up biopharmaceutical company developing new, proprietary drugs for unmet medical needs in diabetes and complications related to diabetes. These drugs have the potential to restate the diabetes market by stopping the progression of diabetes and reversing damage already caused by the disease. Because of their unique immune modulating and anti-inflammatory properties, these therapies may potentially benefit people with type 1 and type 2 diabetes and represent a total available market opportunity of approximately $13 billion. The Company's lead compound, Lisofylline (LSF), has had an excellent safety profile in clinical trials to date. LSF works at the cellular level by improving the function of insulin producing islet cells and protecting them from damage and premature death caused when the body's immune system turns on itself. This autoimmune action is the cause of type 1 diabetes and Latent Autoimmune Diabetes in Adults (LADA), which combined affect approximately three million people in the U.S. About three million people with type 2 diabetes use insulin due to diminished insulin production and an increasing resistance to insulin. A primary focus of DiaKine's research and development is on its next generation of orally bioavailable immune modulators which have an improved spectrum of action to LSF. Two such compounds, DT22669 and DT23552, have been identified for further development and are examples of the extensive library of analogs and new structures in its patent portfolio that await discovery for future indications. | Health Technology |
Allergan Humphrey
Allergan Humphrey Financial ConglomeratesFinance Allergan Humphrey was engaged in making microprocessor based ophthalmic diagnostic equipment. The company was headquartered in San Leandro, CA. | Finance |
| Humphrey Instruments, Inc. | |
Freedom Meditech, Inc.
Freedom Meditech, Inc. Medical SpecialtiesHealth Technology Freedom Meditech, Inc. operates as a medical device company which focuses on the development and commercialization of ophthalmic medical devices. It specializes in devices for the detection, monitoring, and management of chronic diseases, such as diabetes. The company was founded by Craig H. Misrach and Keith D. Ignotz in December 2006 and is headquartered in San Diego, CA. | Health Technology |
OcuMedic, Inc.
OcuMedic, Inc. Medical SpecialtiesHealth Technology OcuMedic, Inc. manufactures lens equipment. The company was founded by Mark Byrne and Paul Byrne and is headquartered in Mullica Hill, NJ. | Health Technology |
